Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
Ethan Basch(UNC Lineberger Comprehensive Cancer Center), Deborah Schrag(Dana-Farber Brigham Cancer Center), Allison M. Deal(Memorial Sloan Kettering Cancer Center), Mark G. Kris(Memorial Sloan Kettering Cancer Center), Amylou C. Dueck(Mayo Clinic in Arizona), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Clifford A. Hudis(American Society of Clinical Oncology)
Cited by 2,297
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k